1w7x: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:
|PDB= 1w7x |SIZE=350|CAPTION= <scene name='initialview01'>1w7x</scene>, resolution 1.80&Aring;
|PDB= 1w7x |SIZE=350|CAPTION= <scene name='initialview01'>1w7x</scene>, resolution 1.80&Aring;
|SITE= <scene name='pdbsite=AC1:So4+Binding+Site+For+Chain+H'>AC1</scene>
|SITE= <scene name='pdbsite=AC1:So4+Binding+Site+For+Chain+H'>AC1</scene>
|LIGAND= <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=413:(S)-[(R)-2-(4-BENZYLOXY-3-METHOXY-PHENYL)-2-(4-CARBAMIMIDOYL-PHENYLAMINO)-ACETYLAMINO]-PHENYL-ACETIC+ACID'>413</scene> and <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>
|LIGAND= <scene name='pdbligand=413:(S)-[(R)-2-(4-BENZYLOXY-3-METHOXY-PHENYL)-2-(4-CARBAMIMIDOYL-PHENYLAMINO)-ACETYLAMINO]-PHENYL-ACETIC+ACID'>413</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>
|ACTIVITY= [http://en.wikipedia.org/wiki/Coagulation_factor_VIIa Coagulation factor VIIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.21 3.4.21.21]  
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Coagulation_factor_VIIa Coagulation factor VIIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.21 3.4.21.21] </span>
|GENE=  
|GENE=  
|DOMAIN=
|RELATEDENTRY=
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1w7x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1w7x OCA], [http://www.ebi.ac.uk/pdbsum/1w7x PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1w7x RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor VIIa inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway.
We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor VIIa inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway.
==Disease==
Known diseases associated with this structure: Factor VII deficiency OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227500 227500]], Myocardial infarction, decreased susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227500 227500]]


==About this Structure==
==About this Structure==
Line 40: Line 40:
[[Category: Weber, L.]]
[[Category: Weber, L.]]
[[Category: Wessel, H P.]]
[[Category: Wessel, H P.]]
[[Category: 413]]
[[Category: CA]]
[[Category: GOL]]
[[Category: SO4]]
[[Category: coagulation]]
[[Category: coagulation]]
[[Category: enzyme complex]]
[[Category: enzyme complex]]
[[Category: serine protease]]
[[Category: serine protease]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 14:53:22 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 00:32:28 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA